Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis

Patrick S. Parfrey, Geoffrey A. Block, Ricardo Correa-Rotter, Tilman B. Drueke, Jurgen Floege, Charles A. Herzog, Gerard M. London, Kenneth W. Mahaffey, Sharon Moe, David C. Wheeler, Glenn M. Chertow

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The effect of the calcimimetic cinacalcet on cardiovascular disease in patients undergoing hemodialysis with secondary hyperparathyroidism was assessed in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events trial. This was the largest (in size) and longest (in duration) randomized controlled clinical trial undertaken in this population. During planning, execution, analysis, and reporting of the trial, many lessons were learned, including those related to the use of a composite cardiovascular primary endpoint, definition of endpoints (particularly heart failure and severe unremitting hyperparathyroidism), importance of age for optimal stratification at randomization, use of unadjusted and adjusted intention-to-treat analysis for the primary outcome, how to respond to a lower-than-predicted event rate during the trial, development of a prespecified analytic plan that accounted for nonadherence and for cointerventions that diminished the power of the trial to observe a treatment effect, determination of the credibility of a subgroup effect, use of adverse effects database to investigate rare diseases, collection of blood for biomarker measurement not designated before trial initiation, and interpretation of the benefits-to-harms ratio for individual patients. It is likely that many of these issues will arise in the planning of future trials in CKD.

Original languageEnglish (US)
Pages (from-to)539-546
Number of pages8
JournalClinical Journal of the American Society of Nephrology
Volume11
Issue number3
DOIs
StatePublished - Mar 7 2016

Fingerprint

Dialysis
Secondary Hyperparathyroidism
Intention to Treat Analysis
Hyperparathyroidism
Random Allocation
Rare Diseases
Renal Dialysis
Cardiovascular Diseases
Randomized Controlled Trials
Heart Failure
Biomarkers
Databases
Therapeutics
Population
Cinacalcet Hydrochloride

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Parfrey, P. S., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J., Herzog, C. A., ... Chertow, G. M. (2016). Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. Clinical Journal of the American Society of Nephrology, 11(3), 539-546. https://doi.org/10.2215/CJN.06370615

Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. / Parfrey, Patrick S.; Block, Geoffrey A.; Correa-Rotter, Ricardo; Drueke, Tilman B.; Floege, Jurgen; Herzog, Charles A.; London, Gerard M.; Mahaffey, Kenneth W.; Moe, Sharon; Wheeler, David C.; Chertow, Glenn M.

In: Clinical Journal of the American Society of Nephrology, Vol. 11, No. 3, 07.03.2016, p. 539-546.

Research output: Contribution to journalArticle

Parfrey, PS, Block, GA, Correa-Rotter, R, Drueke, TB, Floege, J, Herzog, CA, London, GM, Mahaffey, KW, Moe, S, Wheeler, DC & Chertow, GM 2016, 'Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis', Clinical Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 539-546. https://doi.org/10.2215/CJN.06370615
Parfrey, Patrick S. ; Block, Geoffrey A. ; Correa-Rotter, Ricardo ; Drueke, Tilman B. ; Floege, Jurgen ; Herzog, Charles A. ; London, Gerard M. ; Mahaffey, Kenneth W. ; Moe, Sharon ; Wheeler, David C. ; Chertow, Glenn M. / Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. In: Clinical Journal of the American Society of Nephrology. 2016 ; Vol. 11, No. 3. pp. 539-546.
@article{5923ecd50ac14a9587a68611ee76c33d,
title = "Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis",
abstract = "The effect of the calcimimetic cinacalcet on cardiovascular disease in patients undergoing hemodialysis with secondary hyperparathyroidism was assessed in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events trial. This was the largest (in size) and longest (in duration) randomized controlled clinical trial undertaken in this population. During planning, execution, analysis, and reporting of the trial, many lessons were learned, including those related to the use of a composite cardiovascular primary endpoint, definition of endpoints (particularly heart failure and severe unremitting hyperparathyroidism), importance of age for optimal stratification at randomization, use of unadjusted and adjusted intention-to-treat analysis for the primary outcome, how to respond to a lower-than-predicted event rate during the trial, development of a prespecified analytic plan that accounted for nonadherence and for cointerventions that diminished the power of the trial to observe a treatment effect, determination of the credibility of a subgroup effect, use of adverse effects database to investigate rare diseases, collection of blood for biomarker measurement not designated before trial initiation, and interpretation of the benefits-to-harms ratio for individual patients. It is likely that many of these issues will arise in the planning of future trials in CKD.",
author = "Parfrey, {Patrick S.} and Block, {Geoffrey A.} and Ricardo Correa-Rotter and Drueke, {Tilman B.} and Jurgen Floege and Herzog, {Charles A.} and London, {Gerard M.} and Mahaffey, {Kenneth W.} and Sharon Moe and Wheeler, {David C.} and Chertow, {Glenn M.}",
year = "2016",
month = "3",
day = "7",
doi = "10.2215/CJN.06370615",
language = "English (US)",
volume = "11",
pages = "539--546",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "3",

}

TY - JOUR

T1 - Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis

AU - Parfrey, Patrick S.

AU - Block, Geoffrey A.

AU - Correa-Rotter, Ricardo

AU - Drueke, Tilman B.

AU - Floege, Jurgen

AU - Herzog, Charles A.

AU - London, Gerard M.

AU - Mahaffey, Kenneth W.

AU - Moe, Sharon

AU - Wheeler, David C.

AU - Chertow, Glenn M.

PY - 2016/3/7

Y1 - 2016/3/7

N2 - The effect of the calcimimetic cinacalcet on cardiovascular disease in patients undergoing hemodialysis with secondary hyperparathyroidism was assessed in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events trial. This was the largest (in size) and longest (in duration) randomized controlled clinical trial undertaken in this population. During planning, execution, analysis, and reporting of the trial, many lessons were learned, including those related to the use of a composite cardiovascular primary endpoint, definition of endpoints (particularly heart failure and severe unremitting hyperparathyroidism), importance of age for optimal stratification at randomization, use of unadjusted and adjusted intention-to-treat analysis for the primary outcome, how to respond to a lower-than-predicted event rate during the trial, development of a prespecified analytic plan that accounted for nonadherence and for cointerventions that diminished the power of the trial to observe a treatment effect, determination of the credibility of a subgroup effect, use of adverse effects database to investigate rare diseases, collection of blood for biomarker measurement not designated before trial initiation, and interpretation of the benefits-to-harms ratio for individual patients. It is likely that many of these issues will arise in the planning of future trials in CKD.

AB - The effect of the calcimimetic cinacalcet on cardiovascular disease in patients undergoing hemodialysis with secondary hyperparathyroidism was assessed in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events trial. This was the largest (in size) and longest (in duration) randomized controlled clinical trial undertaken in this population. During planning, execution, analysis, and reporting of the trial, many lessons were learned, including those related to the use of a composite cardiovascular primary endpoint, definition of endpoints (particularly heart failure and severe unremitting hyperparathyroidism), importance of age for optimal stratification at randomization, use of unadjusted and adjusted intention-to-treat analysis for the primary outcome, how to respond to a lower-than-predicted event rate during the trial, development of a prespecified analytic plan that accounted for nonadherence and for cointerventions that diminished the power of the trial to observe a treatment effect, determination of the credibility of a subgroup effect, use of adverse effects database to investigate rare diseases, collection of blood for biomarker measurement not designated before trial initiation, and interpretation of the benefits-to-harms ratio for individual patients. It is likely that many of these issues will arise in the planning of future trials in CKD.

UR - http://www.scopus.com/inward/record.url?scp=84960085908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960085908&partnerID=8YFLogxK

U2 - 10.2215/CJN.06370615

DO - 10.2215/CJN.06370615

M3 - Article

C2 - 26614406

AN - SCOPUS:84960085908

VL - 11

SP - 539

EP - 546

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 3

ER -